AU2022244356A1 - Methods and materials for treatment of neisseria gonorrhoeae infection - Google Patents
Methods and materials for treatment of neisseria gonorrhoeae infection Download PDFInfo
- Publication number
- AU2022244356A1 AU2022244356A1 AU2022244356A AU2022244356A AU2022244356A1 AU 2022244356 A1 AU2022244356 A1 AU 2022244356A1 AU 2022244356 A AU2022244356 A AU 2022244356A AU 2022244356 A AU2022244356 A AU 2022244356A AU 2022244356 A1 AU2022244356 A1 AU 2022244356A1
- Authority
- AU
- Australia
- Prior art keywords
- infection
- compound
- group
- alkyl
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163166309P | 2021-03-26 | 2021-03-26 | |
| US63/166,309 | 2021-03-26 | ||
| PCT/US2022/021467 WO2022204231A2 (en) | 2021-03-26 | 2022-03-23 | Methods and materials for treatment of neisseria gonorrhoeae infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022244356A1 true AU2022244356A1 (en) | 2023-09-28 |
Family
ID=83398108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022244356A Pending AU2022244356A1 (en) | 2021-03-26 | 2022-03-23 | Methods and materials for treatment of neisseria gonorrhoeae infection |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250339401A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4313040A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024511945A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230161962A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117396201A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022244356A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3211535A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022204231A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023150719A1 (en) * | 2022-02-03 | 2023-08-10 | Purdue Research Foundation | Alpha-methylene and aminomethyl lactones and lactams for treatment of clostridioides difficile infection (cdi) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005500289A (ja) * | 2001-06-13 | 2005-01-06 | マグナケム インターナショナル ラボラトリーズ, インコーポレイテッド | ラクトン処方物および使用方法 |
| BRPI0620157A2 (pt) * | 2005-12-15 | 2011-12-20 | Activbiotics Pharma Llc | usos de rifamicinas |
| US20210317099A1 (en) * | 2020-04-09 | 2021-10-14 | Purdue Research Foundation | Safer, potent, and fast acting antimicrobial agents |
-
2022
- 2022-03-23 CA CA3211535A patent/CA3211535A1/en active Pending
- 2022-03-23 KR KR1020237031684A patent/KR20230161962A/ko active Pending
- 2022-03-23 CN CN202280024693.0A patent/CN117396201A/zh active Pending
- 2022-03-23 JP JP2023555485A patent/JP2024511945A/ja active Pending
- 2022-03-23 US US18/550,288 patent/US20250339401A1/en active Pending
- 2022-03-23 AU AU2022244356A patent/AU2022244356A1/en active Pending
- 2022-03-23 EP EP22776535.1A patent/EP4313040A4/en active Pending
- 2022-03-23 WO PCT/US2022/021467 patent/WO2022204231A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022204231A3 (en) | 2022-12-29 |
| KR20230161962A (ko) | 2023-11-28 |
| CA3211535A1 (en) | 2022-09-29 |
| CN117396201A (zh) | 2024-01-12 |
| WO2022204231A2 (en) | 2022-09-29 |
| US20250339401A1 (en) | 2025-11-06 |
| EP4313040A2 (en) | 2024-02-07 |
| EP4313040A4 (en) | 2025-02-12 |
| JP2024511945A (ja) | 2024-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11787801B2 (en) | Protein kinase inhibitors, preparation method and medical use thereof | |
| CA2736097C (en) | Carbazole compounds for inhibition of nf-kb activity | |
| JP2022043078A (ja) | 抗菌化合物 | |
| JP2026004421A (ja) | 抗体-薬物複合体に適した毒素分子 | |
| JP2007517861A (ja) | カンナビノイドのキノン派生物の治療使用方法 | |
| US11986459B2 (en) | Methods for the treatment of Mycobacterium infections | |
| JP2025526425A (ja) | 抗体薬物複合体に適した毒素分子 | |
| CA3023171A1 (en) | Phenyl [a]indole[2,3-g]quinolizine compounds, preparation method therefor, pharmaceutical composition, and applications thereof | |
| KR20240055751A (ko) | Bcl-2 패밀리 단백질을 분해하는 화합물 및 이의 의약에서의 응용 | |
| EP4313040A2 (en) | Methods and materials for treatment of neisseria gonorrhoeae infection | |
| CA3238595A1 (en) | 15-pgdh inhibitor and use thereof | |
| EP3369740B1 (en) | New cytidine derivative dimers and applications thereof | |
| CN118406042B (zh) | 含吡啶环的两亲性蛇床子素-季铵盐杂合体及其制备方法和抗菌应用 | |
| CN113248524A (zh) | 一种双吲哚生物碱化合物及其合成方法和用途 | |
| EA034063B1 (ru) | Антибактериальные средства на основе производных ципрофлоксацина | |
| JP2002535276A (ja) | 4−デメチルペンクロメジンのアシル誘導体、その使用及び調製 | |
| US20250195490A1 (en) | Alpha-methylene and aminomethyl lactones and lactams for treatment of clostridioides difficile infection (cdi) | |
| CN119661519B (zh) | 一种具有光动力抗菌作用的新型咔啉季铵盐类化合物的制备方法与应用 | |
| EP1758904B1 (en) | Flavopereirine derivatives for cancer therapy | |
| CN116120327B (zh) | β-榄香烯13,14-位对称的双取代衍生物及其制备方法和应用 | |
| CN103724271B (zh) | 取代咪唑-1-乙烯类化合物及其用途 | |
| Baker et al. | Methods for the treatment of Mycobacterium infections | |
| RU2477127C1 (ru) | Получение квартернизованных производных усниновой кислоты и их биологические свойства | |
| JP2026506166A (ja) | miR-124誘導剤及びその調製方法及び用途 | |
| WO2000055160A1 (fr) | Composition pharmaceutique a base de composes polyaromatiques |